Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of patients with BPDCN who recieved HSCT following induction with tagraxofusp

Naveen Pemmaraju • 9 Feb 2021
TCT 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy with traditionally poor patient outcomes. In this video, Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the outcomes of adult patients with BPDCN who received hematopoietic stem cell transplantation (HSCT) following remission induction with tagraxofusp, a targeted therapy directed to CD123. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Naveen Pemmaraju

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Novel agents and approaches being explored in second-line myelofibrosis
14:29
Novel agents and approaches being explored in second-line myelofibrosis
Claire Harrison et al. • 2 Oct 2026
Evolving treatment landscape in MF: JAK inhibitors, combination therapy, and novel agents
1:39
Evolving treatment landscape in MF: JAK inhibitors, combination therapy, and novel agents
Naveen Pemmaraju • 10 Sep 2026
Exploring JAK inhibitor-based combination strategies in myelofibrosis
1:55
Exploring JAK inhibitor-based combination strategies in myelofibrosis
Naveen Pemmaraju • 10 Sep 2026

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals